Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

Current Atherosclerosis Reports
Jean-Charles FruchartJamila Fruchart-Najib

Abstract

Chronic kidney disease (CKD) poses a major global challenge, which is exacerbated by aging populations and the pandemic of type 2 diabetes mellitus. Much of the escalating burden of CKD is due to cardiovascular complications. Current treatment guidelines for dyslipidemia in CKD prioritize low-density lipoprotein cholesterol management, but still leave a high residual cardiovascular risk. Targeting elevated triglycerides and low plasma high-density lipoprotein cholesterol, a common feature of CKD, could offer additional benefit. There are, however, safety issues with current fibrates (peroxisome proliferator-activated receptor alpha [PPARα] agonists), notably the propensity for elevation in serum creatinine, indicating the need for new approaches. Interactions between the ligand and PPARα receptor influence the specificity and potency of receptor binding, and downstream gene and physiological effects. The peroxisome proliferator-activated receptor alpha modulator (SPPARMα) concept aims to modulate the ligand structure so as to enhance binding at the PPARα receptor, thereby improving the ligand's selectivity, potency, and safety profile. This concept has led to the development of pemafibrate, a novel SPPARMα agent. This review di...Continue Reading

References

Jul 6, 2000·Circulation·UNKNOWN Bezafibrate Infarction Prevention (BIP) study
Mar 3, 2006·The Journal of Clinical Investigation·Philippe LefebvreBart Staels
Mar 21, 2007·The American Journal of Cardiology·Michael H DavidsonTerry A Jacobson
Jun 8, 2007·Bioorganic & Medicinal Chemistry Letters·Yukiyoshi YamazakiJean-Charles Fruchart
Apr 12, 2008·Journal of the American College of Cardiology·James ShepherdUNKNOWN TNT (Treating to New Targets) Investigators
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
Aug 13, 2010·The New England Journal of Medicine·Christoph H SaelyHeinz Drexel
Sep 17, 2010·The New England Journal of Medicine·William J Perkins
Nov 6, 2010·Diabetologia·T M E DavisUNKNOWN Fenofibrate Intervention and Event Lowering in Diabetes Study investigators
Feb 11, 2011·Metabolism: Clinical and Experimental·Leigh PerreaultRobert H Eckel
Apr 20, 2011·Circulation·Michael MillerUNKNOWN Council on the Kidney in Cardiovascular Disease
Oct 23, 2012·Journal of the American College of Cardiology·Min JunVlado Perkovic
Aug 19, 2014·Lancet·Børge G Nordestgaard, Anette Varbo
Sep 4, 2015·Disease-a-month : DM·Richard GargiuloEdgar Lerma
Nov 4, 2016·Nature Reviews. Endocrinology·Barbara GrossBart Staels
Nov 26, 2016·The Lancet. Diabetes & Endocrinology·William G HerringtonUNKNOWN Cholesterol Treatment Trialists' Collaboration
Dec 22, 2016·Reviews in Endocrine & Metabolic Disorders·Matthew R HagerLisa R Tannock
Jan 28, 2017·Journal of Medical Economics·R Brett McQueenJoseph J Saseen
Mar 28, 2017·Expert Opinion on Investigational Drugs·Nicola FerriMassimiliano Ruscica
May 17, 2017·Journal of the American Society of Nephrology : JASN·John W StaniferMichael A Blazing
Aug 5, 2017·International Journal of Public Health·UNKNOWN GBD 2015 Eastern Mediterranean Region Diabetes and Chronic Kidney Disease Collaborators
Feb 25, 2018·Diabetes Care·Christian BommerSebastian Vollmer
Mar 24, 2018·Biochemical and Biophysical Research Communications·Yuta YamamotoHitoshi Shimano

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

REDUCE
IT
PROMINENT
PROVIDE

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.